随着人口老龄化导致癌症发病率上升，精准医疗的重要性不断增长。抗体药物偶联物 (ADC) 通过将细胞毒性剂递送至特定抗原来举例说明靶向治疗。基于这一概念，研究人员开发了抗体-寡核苷酸缀合物（AOC），它将抗体与寡核苷酸结合起来调节基因表达。本综述重点介绍了 AOC 的机制，强调其选择性靶向和调节致病蛋白的独特能力。它还探索了 AOC 的成分及其在肿瘤治疗中的应用，同时解决了制造复杂性、内体逃逸和免疫反应等关键挑战。本文强调了 AOC 在精准肿瘤学中的重要性，并讨论了未来的方向，强调了它们在治疗由基因突变和异常蛋白表达驱动的癌症方面的潜力。版权所有 © 2024。由 Elsevier Ltd 出版。

As cancer incidence rises due to an aging population, the importance of precision medicine continues to grow. Antibody-drug conjugates (ADCs) exemplify targeted therapies by delivering cytotoxic agents to specific antigens. Building on this concept, researchers have developed antibody-oligonucleotide conjugates (AOCs), which combine antibodies with oligonucleotides to regulate gene expression. This review highlights the mechanism of AOCs, emphasizing their unique ability to selectively target and modulate disease-causing proteins. It also explores the components of AOCs and their application in tumor therapy while addressing key challenges such as manufacturing complexities, endosomal escape, and immune response. The article underscores the significance of AOCs in precision oncology and discusses future directions, highlighting their potential in treating cancers driven by genetic mutations and abnormal protein expression.Copyright © 2024. Published by Elsevier Ltd.